With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...
CHICAGO -- Researchers failed to prevent cognitive impairment in people with existing atrial fibrillation (Afib) by going the ...
Michigan’s pension bought Palantir, Intel, and CVS Health stock, while slashing an investment in Bristol Myers in the third ...
Fintel on MSN1d
Wolfe Research Initiates Coverage of Bristol-Myers Squibb Company - Preferred Security (BMYMP) with Peer Perform RecommendationFintel reports that on November 15, 2024, Wolfe Research initiated coverage of Bristol-Myers Squibb Company - Preferred ...
Health stocks slumped on Friday as Wall Street weighed the impact that prominent vaccine skeptic Robert F. Kennedy Jr. could ...
Fintel on MSN2d
Wolfe Research Initiates Coverage of Bristol-Myers Squibb (BMY) with Peer Perform RecommendationFintel reports that on November 15, 2024, Wolfe Research initiated coverage of Bristol-Myers Squibb (NYSE:BMY) with a Peer ...
Bristol-Myers faces a renewed $6.7 billion lawsuit, alleging delayed approval for drugs like Breyanzi, affecting contingent ...
Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...
Bristol Myers Squibb (BMY) has received a recommendation for approval from an expert panel of the European Medicines Agency ...
Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its Augtyro cancer drug in a pair of indications.
The lawsuit accused Bristol Myers of depriving holders of "contingent value rights" (CVR) an extra $9 per share in cash by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback